Brenus Pharma reports favorable tolerability and clinical signals in early preliminary results of first-in-human study for STC-1010 in unresectable metastatic stage MSS CRC patients
Brenus Pharma announces first patients dosed in its first-in-human trial evaluating STC-1010, a next-generation immunotherapy
#AACR2025: Brenus Pharma presents late-breaking preclinical data on its “off-the-shelf” next-generation immunotherapy candidate, STC-1010, now moving to clinic
Brenus Pharma publishes promising proof of concept results of their therapeutic platform in the scientific Frontiers in Oncology journal
Brenus Pharma raises $25 million to accelerate clinical trials of its precision anticancer immunotherapy
